Vertex Pharmaceuticals Announces Webcast of its Presentation at Citi's 5th Annual Biotech Day
,
CAMBRIDGE, Mass., Oct 01, 2010 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it will webcast its participation in an industry panel discussion at Citi's 5th Annual Biotech Day on Tuesday, October 5, 2010 at 10:00 a.m. EDT.
The panel presentation will be webcast live and may be accessed from 'Events & Presentations' on the home page of Vertex's website at www.vrtx.com. A replay of the webcast will also be available on the Company's website for two weeks following the presentation. To ensure a timely connection, it is recommended that users register at least 15 minutes prior to the scheduled webcast.
,
,
CAMBRIDGE, Mass., Oct 01, 2010 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it will webcast its participation in an industry panel discussion at Citi's 5th Annual Biotech Day on Tuesday, October 5, 2010 at 10:00 a.m. EDT.
The panel presentation will be webcast live and may be accessed from 'Events & Presentations' on the home page of Vertex's website at www.vrtx.com. A replay of the webcast will also be available on the Company's website for two weeks following the presentation. To ensure a timely connection, it is recommended that users register at least 15 minutes prior to the scheduled webcast.
,
About Vertex
Vertex Pharmaceuticals Incorporated is a global biotechnology company committed to the discovery and development of breakthrough small molecule drugs for serious diseases. The Company's strategy is to commercialize its products both independently and in collaboration with major pharmaceutical companies. Vertex's product pipeline is focused on viral diseases, cystic fibrosis, inflammation, autoimmune diseases, epilepsy, cancer, and pain. Vertex co-discovered the HIV protease inhibitor, Lexiva, with GlaxoSmithKline.
Lexiva is a registered trademark of the GlaxoSmithKline group of companies.
Vertex's press releases are available at www.vrtx.com.
(VRTX-WEB)
SOURCE: Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals IncorporatedLora Pike, 617-444-6755Director, Investor Relations
Copyright Business Wire 2010
Vertex Pharmaceuticals Incorporated is a global biotechnology company committed to the discovery and development of breakthrough small molecule drugs for serious diseases. The Company's strategy is to commercialize its products both independently and in collaboration with major pharmaceutical companies. Vertex's product pipeline is focused on viral diseases, cystic fibrosis, inflammation, autoimmune diseases, epilepsy, cancer, and pain. Vertex co-discovered the HIV protease inhibitor, Lexiva, with GlaxoSmithKline.
Lexiva is a registered trademark of the GlaxoSmithKline group of companies.
Vertex's press releases are available at www.vrtx.com.
(VRTX-WEB)
SOURCE: Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals IncorporatedLora Pike, 617-444-6755Director, Investor Relations
Copyright Business Wire 2010
No comments:
Post a Comment